Tagged with Clinical

rare diseases The country manager of a leading German chemical and pharmaceutical company sheds light on her company’s activities in the rare diseases segment and speaks about the multiple benefits of promoting home care and greater patient autonomy. You are known for your medicines against diseases that are often neglected, such as…

clinical trials Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers? 2014 was the 55th anniversary of Ahngook’s foundation. I have worked for Ahngook most of my career, although I did…

clinical research Clinical research and access are the name of the game. The Executive Director of the association bringing together the most important research-based pharmaceutical companies discusses how the association has stepped up to partner up with the government and stakeholders to fight for the same objective and create a better health…

clinical research Liz Chatwin came to Korea as general manager of AstraZeneca in the fall of 2013, following a period working at the company’s Chinese affiliate for several years. She contrasts the two markets and highlights the unprecedented quality of Korea’s clinical research capacity. What were your initial impressions of the market…

clinical trials The country manager of a British biopharmaceutical company sheds light on Algeria’s potential for conducting clinical trials and offers his views on the quality of the country’s skilled labour. What is the record of your past fourteen months with AstraZeneca? Since I arrived, I have had two priorities. First, I implemented a new…

clinical trials The general manager of a leading British research-based pharmaceutical company discusses Algeria’s suitability as a destination for pre-clinical and clinical trials and assesses the country’s ability to transition from importer to local producer status Can you please start by briefly introducing GSK in Algeria? GSK activities in Algeria span three…

clinical research The general director of the National Institute for Psychiatry discusses the Institute’s commitment to translating clinical research into better care for patients, the social stigma patients with mental disorders still face in Mexico and the increasing importance of mental health on productivity and the country’s economic development. You have been…

clinical trials The global CEO of Arianne, who herself happens to be American-Algerian, outlines why, in an era of clinical research globalisation, the country has all the right fundamentals in place to establish itself as a leader in conducting clinical trials and how the Algerian genetic code is well suited for testing Western orientated pharmaceutical…

clinical trials LSK Global PS CEO Young-Jack Lee discusses the influence of global CROs on the quality of Korean research, and outlines his own strategy for competing in the marketplace and growth outside of Korea.   When we met you in 2008, you were positive about the growth of Korean CROs and…

Sanofi Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of clinical testing in Korea and why ‘open innovation’ is important for progress and development.   You became general manager of…

partnering The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about his current operations and his vision for the future.     Can you discuss the role that KIT plays today…

clinical trials The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country.   You became president of Astellas Korea in 2011, following a long career at this affiliate. What were the biggest objectives you had when…